Europe Cancer Therapy and Testing Market was valued at USD 45.6 Billion in 2022 and is projected to reach USD 75.4 Billion by 2030, growing at a CAGR of 6.7% from 2024 to 2030.
The European cancer therapy and testing market is undergoing significant transformations, driven by technological advancements and evolving industry requirements. With cancer remaining a leading cause of mortality, the focus has intensified on innovative therapies and precise diagnostic tools to enhance patient outcomes.
One notable development is AstraZeneca's recent progress in breast cancer treatment. Preliminary results from a late-stage trial of Camizestrant, a combination therapy for advanced breast cancer, have shown a significant improvement in progression-free survival. This advancement aligns with the industry's shift towards combination therapies that target multiple pathways, aiming to improve efficacy and reduce resistance.
In parallel, the European Union's health regulator has endorsed Enhertu, a drug developed by AstraZeneca and Daiichi Sankyo, for treating breast cancer in patients who have received endocrine therapy but are unsuitable for further hormone treatments. This approval underscores the industry's commitment to expanding therapeutic options for patients with limited alternatives.
However, the introduction of these innovative therapies presents challenges, particularly concerning cost. Advanced treatments like immunotherapies and antibody-drug conjugates often come with high price tags, placing pressure on healthcare budgets. For instance, Bristol Myers Squibb's Opdivo, an immunotherapy drug, costs nearly $200,000 annually. This financial burden necessitates discussions on sustainable pricing models and reimbursement strategies to ensure patient access without compromising healthcare systems.
On the diagnostics front, the market is projected to reach $12.21 billion by 2031, driven by the rising prevalence of cancer and technological advancements in diagnostic tools. In vitro diagnostics (IVD), including instruments like polymerase chain reaction (PCR) machines and sequencing technologies, are expected to grow rapidly. These tools enable precise detection and characterization of cancer, facilitating personalized treatment approaches.
Despite these advancements, Europe faces challenges in clinical trial participation. Over the past decade, Europe's share of global commercial clinical drug trials has nearly halved, dropping from 22% in 2013 to 12% in 2023. This decline is attributed to complex and lengthy regulatory processes, prompting pharmaceutical companies to favor regions with more streamlined systems, such as the US and China. To reverse this trend, Europe needs to harmonize and simplify its regulatory framework, making it more attractive for clinical research investments.
Furthermore, the potential impact of new EU rules set to take effect in January 2024 has raised concerns among stakeholders. These regulations could drastically reduce the availability of new treatments for rare diseases by imposing stricter limitations on medical trials. Nearly 40 groups, including prominent organizations such as Cancer Patients Europe and the World Federation of Hemophilia, have urged the EU to revise guidelines that undervalue single-arm trials in favor of large-scale randomized control trials (RCTs). Such requirements are considered impractical and unethical for rare diseases due to the small patient populations and severity of conditions.
In the realm of precision medicine, access to quality biomarker testing remains inconsistent across Europe, contributing to health inequalities. Biomarker tests are essential for diagnosing and selecting appropriate treatments for cancer patients. However, disparities in test availability, reimbursement, and quality control hinder the full potential of precision oncology. Addressing these gaps requires coordinated efforts to standardize testing protocols, ensure equitable access, and integrate biomarker testing into routine clinical practice.
In conclusion, while Europe has made strides in advancing cancer therapy and diagnostics, addressing regulatory challenges, cost considerations, and disparities in diagnostic access are crucial for sustaining progress and ensuring that patients benefit from the latest innovations in cancer care.
Get an In-Depth Research Analysis of the Europe Cancer Therapy and Testing Market Size And Forecast [2025-2032]
Â
Invitae
Foundation Medicine
Guardant Health
Illumina
Sysmex
Abingdon Health
Sophia
NanoEntek
BGI
Diagnosis
Exact Sciences
AstraZeneca
Bayer AG
Johnson & Johnson
Pfizer Inc.
Â
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Europe Cancer Therapy and Testing Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Europe Cancer Therapy and Testing Market
Breast Cancer
Prostate Cancer
Lung Cancer
Colorectal Cancer
Leukemia
Others
Chemotherapy
Immunotherapy
Radiation Therapy
Targeted Therapy
Surgery
Hormonal Therapy
Genetic Testing
Biopsy
Imaging Tests
Blood Tests
Molecular Diagnostics
Hospitals
Diagnostic Laboratories
Research Institutions
Oncology Clinics
Home Healthcare
Direct Sales
Online Sales
Retail Pharmacies
Wholesale Distributors
Specialty Clinics
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Cancer Therapy and Testing Market Research Analysis
1. Introduction of the Europe Cancer Therapy and Testing Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Europe Cancer Therapy and Testing Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Europe Cancer Therapy and Testing Market, By Type
6. Europe Cancer Therapy and Testing Market, By Application
7. Europe Cancer Therapy and Testing Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. Europe Cancer Therapy and Testing Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Europe Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/